1 citations · 1 across the 4 of their papers we have counts for
4 papers
Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid drugs in Alzheimer's disease: a Bayesian meta-analysis
Sa Ren, Janharpreet Singh, Sandro Gsteiger +8
The use of amyloid-beta (A) clearance to support regulatory approvals of drugs in Alzheimer's disease (AD) remains controversial. We evaluate A as a potential trial-level sur…
Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis
Chinyereugo M Umemneku-Chikere, Lorna Wheaton, Heather Poad +7
Objective: We aimed to develop a meta-analytic model for evaluation of predictive biomarkers and targeted therapies, utilising data from digital sources when individual participant…
Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations
Lorna Wheaton, Dan Jackson, Sylwia Bujkiewicz
During drug development, evidence can emerge to suggest a treatment is more effective in a specific patient subgroup. Whilst early trials may be conducted in biomarker-mixed popula…
Using Bayesian Evidence Synthesis Methods to Incorporate Real World Evidence in Surrogate Endpoint Evaluation
Lorna Wheaton, Anastasios Papanikos, Anne Thomas +1
Objective: Traditionally validation of surrogate endpoints has been carried out using RCT data. However, RCT data may be too limited to validate surrogate endpoints. In this paper,…